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Abstract: Background: Hyperlipidemia increases mortality and is common with kidney-disease. New-onset 
hyperlipidemia (NOHL) among patients wait-listed and after transplantation may impact costs and graft-survival of 
patients with kidney disease. Methods: Using the United States Renal Data System, we compared the costs to Medicare 
associated with or without NOHL in wait-listed patients in the second and first year pre-transplant and transplanted 
patients in the first and second year post-transplant. We also examined the impact on graft-survival of NOHL. Results: 
New onset hyperlipidemia was especially expensive when it occurred well before transplantation. When compared with 
individuals with no hyperlipidemia, patients with early onset hyperlipidemia cost an extra $15,228 in the two years before 
transplantation and an extra $14,673 in the two years following transplantation. As has been found in prior studies, 
patients without any NOHL had the worst graft survival rates. Conclusions: Although NOHL was associated with 
increased pre- and post-transplant costs, patients diagnosed with NOHL between the second year before and second year 
after transplantation experienced higher graft-survival rates than those without NOHL by 2-years post-transplantation. 
Prior studies attribute this relationship to inflammation and malnutrition, which result in lower cholesterol levels and 
worse outcomes. 
Keywords: Renal transplantation, hyperlipidemia, graft survival. 
INTRODUCTION 
 Hyperlipidemia, elevated blood lipid levels, is a prevalent 
condition among patients with end stage renal disease 
(ESRD) [1] and has been shown to be associated with main-
tenance immunosuppression [2], atherosclerosis and cardio-
vascular mortality [3-5]. New-onset hyperlipidemia (NOHL) 
may impact costs and graft-survival. This study builds on 
prior research that has evaluated the costs and outcomes 
associated with other diseases, such as diabetes, sepsis, and 
pneumonia [6-7].  
 An appropriate determination of the true incidence of 
post-transplant hyperlipidemia (PTHL) has been difficult. 
Satterthwaite reported one year incidences of hypercholes-
terolemia of 68% and 26% for renal transplant patients on 
cyclosporine- and tacrolimus-based immunosuppression, 
respectively [8]. In the US Multicenter Tacrolimus Renal 
Trial, the need for lipid lowering agents at three years was 
39% and 14% for patients on cyclosporine- and tacrolimus- 
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based immunosuppression, respectively [9]. In the European 
Multicenter Tacrolimus Renal Trial, hypercholesterolemia at 
four years was present in 30% and 10% of patients on 
cyclosporine- and tacrolimus-based immunosuppression, res-
pectively [10]. However, these studies used different defini-
tions of hyperlipidemia, had varying patient populations, and 
employed varying immunosuppressive regimens. The current 
study identified the incidence of PTHL by comparing the 
incidence of hyperlipidemia among transplant recipients to 
that of patients on dialysis. 
 The appropriate measure of the incidence of PTHL 
actually attributable to transplantation should be based on the 
difference between the observed incidence of PTHL and the 
incidence which would have been expected to occur in a 
baseline similar population that had not been transplanted. 
“Wait-listed” patients, that subset of patients on dialysis 
eligible for a transplant but who have not yet received one, 
define the most appropriate comparison group when deter-
mining the baseline incidence of new onset hyperlipidemia 
(NOHL). While the incidence of NOHL in “wait-listed” 
patients has not been determined previously, the high 
correlation between hyperlipidemia and ESRD suggests that 
the incidence of NOHL among “wait-listed” patients may be 
higher than the incidence of NOHL in the general population 
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[11]. At the same time, however, the relatively high health 
status of the “wait-listed” kidney patients suggests their 
NOHL incidence may be lower than that reported among the 
overall ESRD population.  
 The development of NOHL in wait-listed and PTHL in 
transplanted patients is likely to be associated with signi-
ficant costs, due to the association among hyperlipidemia, 
cardiovascular and peripheral vascular complications [3-5]. 
Because Medicare is the primary payer for most patients 
with ESRD, the implications of the incidence and the costs 
of NOHL and PTHL and impact on graft-survival has 
national significance. 
 The primary objective of this study was to determine the 
costs of NOHL based on the time of onset relative to the 
time of transplantation. We used national data to calculate 
the incidence and Medicare payments associated with NOHL 
from two years pre-transplant to two years post-transplant. 
Each of these calculations was performed for patients with 
NOHL two years pre-transplant, one year pre-transplant, one 
year post-transplant, two years post-transplant, and for 
patients with no hyperlipidemia between two years pre-
transplant   and   two  years  post-transplant.  In  addition, we  
examined graft survival rates by the time of hyperlipidemia 
onset relative to the time of transplantation.  
METHODS 
 We examined data from the 2003 release of the United 
States Renal Data System (USRDS) allowing for two-years 
of follow-up [12]. These data permit examination of the 
association of clinical outcomes with characteristics of 
donors, recipients, and protocols, and correlation with 
outcomes with the actual costs to Medicare. 
 In the 2003 release of the USRDS database, we identified 
37,906 first, single-organ renal transplants from cadaveric 
donors to recipients 20-65 years old which were performed 
since 1995 and for which Medicare was the primary payer. 
Of the 37,906 subjects at transplant, 22,556 (59.5%) were 
followed at 2 years (730 days) before transplant; 30,356 
(80.1%) were followed at 1 year (365 days) before trans-
plant; 31,361 (82.7%) were followed at 1 year after trans-
plant; and 25,939 (68.4%) were followed at two years after 
transplant (Fig. 1). 
 This research used the time of onset of NOHL, to cons-
truct patient cohorts. A diagnosis of NOHL was defined as 
 
 
 
 
Fig. (1). Hyperlipidemia claims per 100 patient years among patients with NOHL first year pre-transplant and first year post-transplant. 
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the date on which the second ICD-9-CM code between 272.0 
and 272.4 was reported on any claim after one year’s 
experience without any such claim. These ICD-9-CM codes 
correspond to “Pure Hypercholesterolemia” and “Mixed 
Hyperlipidemia”, respectively. The analysis is restricted to 
Medicare patients, and therefore non-Medicare claims are 
not captured in the current study. 
 We constructed five cohorts according to key time points 
and the occurrence of NOHL in the identified subjects. The 
key time points were the day of transplant (“Day 0”), 2 years 
(730 days) before transplant, 1 year (365 days) before 
transplant, 1 year (365 days) after transplant, and 2 years 
(730 days) after transplant. Four time periods were defined 
and used to divide the groups of subjects with NOHL further 
into the following four cohorts: 1. NOHL within the second 
year before transplant; 2. NOHL within the first year before 
transplant; 3. NOHL within the first year after transplant; 
and 4. NOHL within the second year after transplant, with 
5,222, 4,346, 7,438, and 1,860 patients followed at trans-
plantation, respectively. The fifth cohort included those 
transplant subjects who had no hyperlipidemia diagnosis 
during any of the four years, with 19,040 patients followed 
after transplantation. 
 Ideally this fifth cohort would be comprised of patients 
with no hyperlipidemia onset at all. However, given our 
cohort definitions it is possible that these patients may have 
had hyperlipidemia diagnosed prior to the two year pre-
transplant period studied. There is no variable provided in 
the USRDS data that defines the patient’s hyperlipidemia 
status at transplant, and some patients are not followed prior 
to two years pre-transplant. Therefore, the best definition we 
could provide was the absence of hyperlipidemia in the 
physician/supplier and institutional claims. 
 The incidence of hyperlipidemia claims was plotted for 
each day pre- and post-transplant. Average accumulated 
post-transplant costs were calculated using a method similar 
to that of Kaplan-Meier survival curves. Specifically, the 
Average Accumulated Medicare Payments (AAMPs) for the 
first day post-transplant were set to $0 since no patient was 
discharged that quickly. For each subsequent day “t”, the 
average accumulated payments equaled the average 
accumulated payments of the previous day plus the average 
incremental payments on day “t”. The average incremental 
payments on day “t” were calculated as the total Medicare 
payments made on day “t” (MPt) divided by the number of 
individuals remaining uncensored on day “t” (nt): 
AAMPt = AAMPt-1 + (MPt/ nt) -730>t>730 
 We also calculated the graft survival rates over the two 
years following transplantation using Kaplan-Meier graft 
survival curves. 
RESULTS 
Cohort Characteristics and Incidence 
 The five cohorts used in this study differed with respect 
to various recipient, donor, and procedure characteristics on 
univariate analyses (Table 1). Patients with NOHL during 
the second pre-transplant year peaked at 554 diagnoses per 
100 patient years and returned to a baseline of 224 by the 
end of the second post-transplant year. Patients with NOHL 
identified in the first year before transplantation peaked at 
617 hyperlipidemia diagnoses per 100 person years shortly 
after transplantation and returned to a baseline of approxi-
mately 209 diagnoses per 100 person years in the second 
post-transplant year (Fig. 1). Patients with NOHL during the 
first post-transplant year peaked at 994 and had not returned 
to the 209 baseline by the end of the second post-transplant 
year (Fig. 1). Patients with NOHL during the second post-
transplant year peaked at 714 diagnoses per 100 person-years 
by the end of the second post-transplant year. These results 
show that patients with hyperlipidemia identified before 
transplantation had fewer hyperlipidemia diagnoses after 
transplantation than did those with NOHL post-transplan-
tation. These incidence rates suggested by the claims data are 
somewhat lower than those observed by Tse et al. in single 
center studies [13]. While NOHL is less prevalent among 
wait-listed patients, we found a non-zero hyperlipidemia 
incidence rate pre-transplant, consistent with Tse et al. [13]. 
Hyperlipidemia and Average Accumulated Medicare 
Payments (AAMPs) 
 The AAMPs represent the accumulation of all Medicare 
payments for transplant recipients in each cohort (Fig. 2). 
Compared to patients without NOHL during the two years 
before or two years after transplantation, patients with 
NOHL in the second year before transplantation cost Medi-
care an additional $15,228 (p<0.001) in the two years before 
transplantation and an additional $14,673 (p<0.001) by the 
end of the second year post-transplant. For patients who 
developed NOHL during the first year before transplantation, 
the additional Medicare payments were $2,443 in the two 
years before transplantation and $6,935 in the two years 
following transplantation (p<0.001). Patients who developed 
NOHL during the first post-transplant year cost Medicare an 
additional $2,722 (p<0.001) by the end of the second post-
transplant year. There was no significant cost difference 
between patients without NOHL and patients with NOHL 
during the second post-transplant year. These results suggest 
that early onset hyperlipidemia is particularly expensive. The 
AAMP cumulative cost curves used to measure the costs 
associated with the timing of hyperlipidemia onset do not 
allow for the identification of specific factors that are 
responsible for the increased costs. 
Confirmatory Multivariate Regression 
 Multivariate regression analyses controlling for signifi-
cant donor, recipient, and procedure characteristics as des-
cribed in Table 1 confirmed the cost differences (Table 2). 
Stepwise regression results showed that developing hyper-
lipidemia during the second year pre-transplant cost Medi-
care an additional $8,961 (p<0.001) by the end of the second 
post-transplant year compared to no NOHL. Similarly, 
NOHL during the first pre-transplant year cost an additional 
$4,129 (p<0.001). These estimates were smaller in magni-
tude than those implied by Fig. (2), as might be expected 
given that patients who developed hyperlipidemia were more 
likely to have other costly diseases, such as diabetes, cardio-
vascular disease, or peripheral artery disease. The two-year 
accumulated costs of patients with NOHL during the first or 
second post-transplant years were not significantly different 
8     The Open Transplantation Journal, 2010, Volume 4 Woodward et al. 
from the costs of patients without NOHL (P=0.373, 0.571 
respectively). 
Association Between NOHL on Graft Survival 
 Kaplan-Meier plots depicting the graft survival rates for 
each of the five cohorts, are shown in Fig. (3). Patients who 
did not develop NOHL during the study period had lower 
graft survival rates at 2 years post-transplant than patients 
who did develop NOHL during the four-year period. Thus, 
among those who developed NOHL during the study period, 
patients with NOHL in the second year pre-transplant 
experienced a two year graft survival rate of 80.25% 
compared to 86.60% among those with NOHL in the second 
year post-transplant. The graft survival rate among patients 
with NOHL in the first pre-transplant year was 83.66%, 
while the graft survival rate among patients with NOHL in 
the first post-transplant year was 85.94%. Importantly, the 
results from “death censored” models were not significantly 
different.  
 Cox proportional hazard models confirmed the Kaplan-
Meier plots. Hazard ratios indicated that NOHL is associated 
with a lower occurrence of graft failure. Recipients who 
were older, black, had histories of other diseases (such as 
diabetes, hepatitis C, peripheral vascular disease, or cardio-
vascular disease), were recipients of a black donor, were 
highly HLA-sensitized recipients with panel reactive 
antibodies greater than 50%, had received cadaveric donors, 
Table 1. Descriptive Statistics of Hyperlipidemia Cohorts 
 
Variable 
NOHL 2
nd
 Year before 
Tx 
NOHL 
1
st
 year 
before 
Tx 
NOHL 
1
st
 Year 
after Tx 
NOHL 
2
nd
 Year after 
Tx 
No 
NOHL 
Significance of 
Overall Differences 
Recipient age <= 17 0.38 1.10 0.81 1.56 6.29 ** 
45<=Recipient age<60 34.76 35.43 37.12 36.99 30.13 ** 
Recipient age>=60 32.98 28.92 21.75 18.28 15.81 ** 
Recipient male 58.89 58.15 57.53 58.39 61.47 ** 
Recipient black 28.46 24.90 27.80 28.98 31.87 ** 
Recipient Hispanic 15.35 13.30 13.84 13.94 14.20  
Living donor 18.17 30.72 25.93 26.56 27.02 ** 
Donor age (years) 38.08 38.21 37.72 37.65 36.66 ** 
Donor male 55.61 52.36 54.51 54.45 54.07 ** 
Donor black 11.82 11.62 11.94 13.82 14.18 ** 
Donor Hispanic 13.39 11.34 12.19 12.99 12.30 * 
Cyclosporine 49.39 53.34 55.65 58.76 46.04 ** 
Azathioprine 10.82 14.36 13.51 21.18 24.22 ** 
Mycophenolate mofetil 70.93 68.87 66.43 62.37 59.16 ** 
Warm ischemia time (minutes) 24.50 22.49 23.12 22.67 23.39  
Cold ischemia time (hours) 19.56 18.99 19.01 18.90 18.87  
Number of HLA mismatches 3.39 3.11 3.26 3.23 3.19 ** 
Hepatitis C at tx 5.78 5.04 4.97 5.91 6.20 ** 
Diabetes as a cause of ESRD 28.88 28.92 21.61 21.67 18.36 ** 
History of diabetes 33.86 33.85 25.21 23.49 19.42 ** 
History of cardiovasc. disease 3.12 2.81 2.23 1.72 1.75 ** 
History of peripheral vasc. disease 5.74 4.79 3.20 3.98 3.04 ** 
Donor CMV+ / Recipient CMV + 46.45 43.08 41.27 42.10 41.10 ** 
Donor CMV- / Recipient CMV + 16.49 17.62 18.65 19.59 19.68 * 
Donor CMV+ / Recipient CMV - 24.6 25.82 24.66 23.05 23.29 ** 
Panel reactive antibody percent 
>=50 
4.08 3.29 3.83 3.60 4.42 ** 
 n=5,222 n=4,346 N=7,438 n=1,860 n=19,040  
When constructing explanatory variables, missing values were coded as the absence of the status or condition. * and ** denote statistical significance at the 
95% and 99% confidence level, respectively. Table values are percentages unless otherwise labeled. 
 
The Incidence and Cost of Hyperlipidemia The Open Transplantation Journal, 2010, Volume 4     9 
or were donor and recipient seropositive for cytomegalovirus 
had higher probabilities of graft failure. Recipients who 
received azathioprine, cyclosporine or mycophenolate com-
pared to those who did not receive each as well as those who 
received transplants more recently had higher rates of graft-
survival. 
 
Fig. (2). Average accumulated Medicare payments. 
Note: The green line denoting “HL 1st year after tx” is almost directly underneath the light blue line denoting “HL 2nd year after tx”. 
 
Fig. (3). Graft survival by hyperlipidemia onset time. 
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Table 2. Confirmatory Stepwise Multivariate Regression: 
Significant Determinants of Two-Year Accumulated 
Medicare Payments 
 
Variable 
Parameter  
Estimate in $ 
P-Value 
Intercept 47,824 <.0001 
NOHL 2nd year pre-transplant 8,961 <.0001 
NOHL 1st year pre-transplant 4,129 0.0007 
Recipient age ? 17 9,708 <.0001 
Recipient age between 45 and 60 2,439 0.0041 
Recipient age ? 60 5,280 <.0001 
Donor age 286 <.0001 
Recipient black 5,791 <.0001 
Hepatitis C at transplant 12,103 <.0001 
Donor black 3,969 0.0005 
History of diabetes 5,646 0.0001 
History of peripheral vascular 
disease 
6,300 0.0011 
History of cardiovascular 
disease 
7,203 0.0052 
Panel reactive antibody percent 
? 50 9,504 <.0001 
Diabetes as cause of ESRD 4,183 0.0042 
Number of HLA mismatches 1,049 <.0001 
Azathioprine (compared to “no 
Aza”) 
-5,079 <.0001 
Cyclosporine (Compared to “no 
CsA”) 
-5,417 <.0001 
Cadaveric donor 5,963 <.0001 
Donor CMV+/Recipient CMV- 2,154 0.0215 
Recipient male -2,377 0.0016 
Year 1996 (compared to year 
1995) 
3,963 <.0001 
Year 2000 (compared to year 
1995) 
-2,805 0.0375 
Variables found to be insignificant were “NOHL 1st year post transplant”, 
“NOHL 2nd year post transplant”, recipient Hispanic, donor male, donor 
Hispanic, Mycofenolate mofetil (compared to “no MMF), warm ischemia 
time, and cold ischemia time . (Adjusted R2 = 0.0401). 
 
 Our result that NOHL was associated with lower 
occurrences of graft failure is consistent with prior research 
that suggested that this association may be attributed to 
inflammation and malnutrition, which are associated with 
lower lipid levels and adverse outcomes [14,15]. Among 
those patients with NOHL during our study period, earlier 
onset of NOHL was associated with higher rates of graft 
failure. Alternatively, if patients without NOHL are being 
treated for more serious co-morbidities consistent with 
higher rates of graft failure, such as hepatitis or pneumonia, 
and clinicians are not billing for the hyperlipidemia treat-
ment, then our use of claims data will miss these potential 
cases of NOHL. 
CONCLUSIONS 
 This study compared costs and graft-survival related to 
NOHL based on the time of onset relative to transplantation. 
Our results indicated that patients diagnosed with NOHL in 
the second pre-transplant year incurred additional two-year 
accumulated Medicare payments of $14,673 compared to 
patients with no hyperlipidemia diagnoses. Patients diag-
nosed with NOHL in the first pre-transplant year incurred 
additional two-year accumulated Medicare payments of 
$6,935. Although NOHL was associated with increased pre- 
and post-transplant costs, patients diagnosed with NOHL 
between the second year before and second year after 
transplantation experienced higher graft survival rates than 
those with no NOHL diagnoses during that time period. 
 Our findings are important. Development of hyperlipi-
demia is expensive. At least one new immunosuppressive 
agent, sirolimus, is associated with increased incidences of 
hyperlipidemia, but improvements in short-term renal func-
tion and no significant impact on cardiovascular mortality 
[16,17]. Therefore, in assessing the costs and benefits of 
these immunosuppressive agents, researchers must take into 
account the costs of the associated increases in the incidence 
of hyperlipidemia. The impact on long-term costs and 
outcomes remains to be determined.  
 Our study has limitations. It was retrospective, relied on 
registry data, and did not assess costs and outcomes beyond 
2-years post-transplantation. Claims data may not reflect the 
true incidence of hyperlipidemia, especially if patients are 
being screened and treated for hyperlipidemia in conjunction 
with other treatments. The hyperlipidemia incidence found in 
our study was lower than those typically found in single 
center studies, however it was not zero. The diagnostic codes 
for our study did not take into consideration the impact of 
dyslipidemia such as low high-density lipoproteinemia, 
which is a major factor for cardiovascular disease. The 
prevalence of diagnosed dyslipidemia was relatively low 
compared to hyperlipidemia. We did not compare the impact 
of maintenance peritoneal dialysis and hemodialysis on costs 
or graft-survival. However, we doubt that this would have 
been significant overall given the relatively small percentage 
of patients receiving peritoneal dialysis in the U.S. We also 
did not directly compare the use of cyclosporine to tacro-
limus for maintenance immunosuppression. Use of cyclos-
porine is associated with more hyperlipidemia than use of 
tacrolimus. However we did compare the use of cyclosporine 
to those who did not receive cyclosporine. Future work could 
consider differences in costs and outcomes by type of 
medication rather than by the timing of hyperlipidemia 
onset. Finally, the data do not allow assessment of the use of 
“statins” which may impact costs and outcomes.  
 Although NOHL was associated with increased pre- and 
post-transplant costs, patients diagnosed with NOHL bet-
ween the second year before and second year after 
transplantation experienced higher graft-survival rates than 
those with no-NOHL during that time period. Prior studies 
have attributed this association to malnutrition and inflam-
mation, which may lower cholesterol levels but have adverse 
effects on graft survival.  
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ABBREVIATIONS 
AAMP = Average Accumulated Medicare Payments 
ESRD = End Stage Renal Disease 
NOHL = New Onset Hyperlipidemia 
PTHL = Post Transplant Hyperlipidemia 
USRDS = United States Renal Data System 
 
APPENDIX 
 
Fig. (A1). Number of patients followed by the timing of NOHL. 
 
 
Fig. (A2). Hyperlipidemia claims per 100 patient years among patients with NOHL second year pre-transplant. 
 
 
Fig. (A3). Hyperlipidemia claims per 100 patient years among patients with NOHL second year post-transplant. 
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Table A1. Average Accumulated Medicare Payments 
 
 Day -730 Day -365 Day 365 Day 730 
-$77,065 -$39,814 $67,487 $87,783 
NOHL 2nd year before tx 
(4,463) (5,222) (3,947) (3,008) 
-$64,280 -$37,249 $61,508 $80,045 
NOHL 1st year before tx 
(2,315) (3,427) (3,398) (2,717) 
-$58,574 -$30,912 $56,670 $75,832 
NOHL 1st year after tx 
(4,085) (5,565) (6,358) (4,862) 
-$58,457 -$31,046 $51,110 $71,943 
NOHL 2nd year after tx 
(1,028) (1,443) (1,860) (1,710) 
-$61,837 -$32,636 $56,751 $73,110 
No NONo NOHL 
(10,665) (14,699) (15,773) (13,642) 
The number of patients followed in each cohort on each day is given in parentheses.  
 
Table (A2). Cox Proportional Hazard Estimates of Graft Survival 
 
Variable Parameter Estimate p-Value 
Hazard Ratio 
95% Confidence Interval 
NOHL 2nd year pre-transplant ???????? 0.0003 0.771 0.925 
NOHL 1st year pre-transplant ???????? <.0001 0.680 0.837 
NOHL 1st year post-transplant ???????? <.0001 0.525 0.629 
NOHL 2nd year post-transplant ???????? <.0001 0.474 0.644 
Recipient age between 45 and 60 ??????? <.0001 1.088 1.250 
Recipient age ? 60 ??????? <.0001 1.366 1.600 
Donor age ??????? <.0001 1.009 1.013 
Recipient black ??????? <.0001 1.138 1.298 
Hepatitis C at transplant ??????? 0.0009 1.078 1.340 
Donor black ??????? <.0001 1.107 1.314 
History of diabetes ?????? 0.0002 1.065 1.224 
History of peripheral vascular disease ??????? 0.0046 1.064 1.409 
History of cardiovascular disease ?????? 0.0029 1.096 1.556 
Panel reactive antibody percent ? 50 ??????? <.0001 1.342 1.730 
Number of HLA mismatches ??????? <.0001 1.057 1.095 
Azathioprine (compared to “no Aza”) ???????? <.0001 0.704 0.834 
Cyclosporine (compared to “no CsA”) ???????? <.0001 0.811 0.916 
Mycophenolate mofetil (compared to "no MMF”) ???????? <.0001 0.691 0.800 
Cadaveric donor ??????? <.0001 1.403 1.697 
Donor CMV+/Recipient CMV- ??????? 0.0061 1.030 1.194 
Donor male ???????? <.0001 0.814 0.917 
Year 2000 (compared to year 1995) ???????? 0.0003 0.709 0.902 
Year 2001 (compared to year 1995) ???????? 0.0011 0.687 0.910 
N=25,055. Variables listed in Table 1 that do not appear in this model were found to be insignificant. (Overall model significance p<0.0001). 
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